Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
Retrieved on:
Tuesday, March 15, 2022
Survival, Immunoglobulin G, European Medicines Agency, Mortality, Commercial, Quality of life, Program, Patient, NUB, Nasdaq Stockholm, ESRD, EU, Hansa, AMNOG, State, Nasdaq, National Association, Chronic kidney disease, Risk, Dialysis, Kidney transplantation, EMA, Antibody, Hlas, Safety, Transplant, Degenerative disease, Medicine, Kidney disease, Company, Research, Cancer, CEO, DSA, Kidney failure, European Market Infrastructure Regulation, Priority, Kidney, European, Health insurance, Dentistry, Pharmaceutical industry, Medical device, Agency, Imlifidase
This completes, within the foreseen 12 month timeline, the AMNOG (Medicines Market Reorganization Act) process for Idefirix in Germany.
Key Points:
- This completes, within the foreseen 12 month timeline, the AMNOG (Medicines Market Reorganization Act) process for Idefirix in Germany.
- At Hansa, our commitment is to significantly improve the lives of highly sensitized patients in Germany who are waiting for a potentially life-saving kidney transplant," says Sren Tulstrup, President and CEO, Hansa Biopharma.
- "Highly sensitized kidney patients have previously had very limited access to kidney transplants due to the lack of effective desensitization treatments, and they often have no alternative but to remain on long-term dialysis."
- Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients.